Comparison between super-responders and non-super-responders in psoriasis under adalimumab treatment: a real-life cohort study on the effectiveness and drug survival over one-year

References

• Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323(19):1–8. doi: 10.1001/jama.2020.4006.
   Web of Science ®Google Scholar
• Dalgard FJ, Gieler U, Tomas-Aragones L, et al. The psychological burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countries. J Invest Dermatol. 2015;135(4):984–991. doi: 10.1038/jid.2014.530.
   PubMed Web of Science ®Google Scholar
• Gisondi P, Puig L, Richard MA, et al. Quality of life and stigmatization in people with skin diseases in Europe: a large survey from the ‘burden of skin diseases’ EADV project. J Eur Acad Dermatol Venereol. 2023;37 Suppl 7:6–14. doi: 10.1111/jdv.18917.
   PubMed Web of Science ®Google Scholar
• Ghoreschi K, Balato A, Enerbäck C, et al. Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis. Lancet. 2021;397(10275):754–766. doi: 10.1016/S0140-6736(21)00184-7.
   PubMed Web of Science ®Google Scholar
• Strober B, Papp KA, Lebwohl M, et al. Clinical meaningfulness of complete skin clearance in psoriasis. J Am Acad Dermatol. 2016;75(1):77–82 e7. doi: 10.1016/j.jaad.2016.03.026.
   PubMed Web of Science ®Google Scholar
• Thomas SE, van den Reek J, Seyger MMB, et al. How to define a ‘super-responder’ to biologics in psoriasis studies. Br J Dermatol. 2023;189(5):621–622. doi: 10.1093/bjd/ljad280.
   PubMed Web of Science ®Google Scholar
• Loft N, Egeberg A, Rasmussen MK, et al. Prevalence and characterization of treatment-refractory psoriasis and super-responders to biologic treatment: a nationwide study. J Eur Acad Dermatol Venereol. 2022;36(8):1284–1291. doi: 10.1111/jdv.18126.
   PubMed Web of Science ®Google Scholar
• Reich K, Gordon KB, Strober B, et al. Super-response to guselkumab treatment in patients with moderate-to-severe psoriasis: age, body weight, baseline psoriasis area and severity index, and baseline investigator’s global assessment scores predict complete skin clearance. J Eur Acad Dermatol Venereol. 2022;36(12):2393–2400. doi: 10.1111/jdv.18474.
   PubMed Web of Science ®Google Scholar
• Gargiulo L, Ibba L, Malagoli P, et al. A risankizumab super responder profile identified by long-term real-life observation-IL PSO (ITALIAN LANDSCAPE PSORIASIS). J Eur Acad Dermatol Venereol. 2023;38(1):e113–e116. doi: 10.1111/jdv.
   PubMedGoogle Scholar
• Ruiz-Villaverde R, Rodriguez-Fernandez-Freire L, Armario-Hita JC, et al. Super responders to guselkumab treatment in moderate-to-severe psoriasis: a real clinical practice pilot series. Int J Dermatol. 2022;61(8):1029–1033. doi: 10.1111/ijd.15784.
   PubMed Web of Science ®Google Scholar
• Gordon KB, Langley RG, Leonardi C, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol. 2006;55(4):598–606. doi: 10.1016/j.jaad.2006.05.027.
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Merola JF, Reich K, et al. Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate-to-severe plaque psoriasis: results from EXCEED, a randomized, double-blind head-to-head monotherapy study. Br J Dermatol. 2021;185(6):1124–1134. doi: 10.1111/bjd.20413.
   PubMed Web of Science ®Google Scholar
• Mahil SK, Ezejimofor MC, Exton LS, et al. Comparing the efficacy and tolerability of biologic therapies in psoriasis: an updated network meta-analysis. Br J Dermatol. 2020;183(4):638–649. doi: 10.1111/bjd.19325.
   PubMed Web of Science ®Google Scholar
• Gasslitter I, Kirsten N, Augustin M, et al. Successful intra-class switching among IL-17 antagonists: a multicentre, multinational, retrospective study. Arch Dermatol Res. 2019;311(5):421–424. doi: 10.1007/s00403-019-01907-y.
   PubMed Web of Science ®Google Scholar
• Conti A, Peccerillo F, Amerio P, et al. Efficacy and safety of switching to ixekizumab in secukinumab nonresponder patients with psoriasis: results from a multicentre experience. Br J Dermatol. 2019;180(6):1547–1548. doi: 10.1111/bjd.17580.
   PubMed Web of Science ®Google Scholar
• Strober B, Ryan C, van de Kerkhof P, et al. Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council. J Am Acad Dermatol. 2020;82(1):117–122. doi: 10.1016/j.jaad.2019.08.026.
   PubMed Web of Science ®Google Scholar
• Cai L, Gu J, Zheng J, et al. Efficacy and safety of adalimumab in Chinese patients with moderate-to-severe plaque psoriasis: results from a phase 3, randomized, placebo-controlled, double-blind study. J Eur Acad Dermatol Venereol. 2017;31(1):89–95. doi: 10.1111/jdv.13746.
   PubMed Web of Science ®Google Scholar
• Gisondi P, Fargnoli MC, Amerio P, et al. Italian adaptation of EuroGuiDerm guideline on the systemic treatment of chronic plaque psoriasis. Ital J Dermatol Venerol. 2022;157(Suppl. 1 to No. 1):1–78. doi: 10.23736/S2784-8671.21.07132-2.
   PubMedGoogle Scholar
• Warren RB, Smith CH, Yiu ZZN, et al. Differential drug survival of biologic therapies for the treatment of psoriasis: a prospective observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). J Invest Dermatol. 2015;135(11):2632–2640. doi: 10.1038/jid.2015.208.
   PubMed Web of Science ®Google Scholar
• Alberti KG, Zimmet P, Shaw J. The metabolic syndrome–a new worldwide definition. Lancet. 2005;366(9491):1059–1062. doi: 10.1016/s0140-6736(05)67402-8.
   PubMed Web of Science ®Google Scholar
• Geale K, Henriksson M, Jokinen J, et al. Association of skin psoriasis and somatic comorbidity with the development of psychiatric illness in a nationwide Swedish study. JAMA Dermatol. 2020;156(7):795–804. doi: 10.1001/jamadermatol.2020.1398.
   PubMed Web of Science ®Google Scholar
• Do anti-psoriatic drugs work better in women than men? Br J Dermatol. 2021;185(6):e200–e13. doi: 10.1111/bjd.20787.
   PubMedGoogle Scholar
• Menendez Sanchez M, Muniz de Lucas A, Perez Fernandez E, et al. Super-responders in psoriasis under interleukin 23 inhibitor treatments, experience in two centres. J Eur Acad Dermatol Venereol. 2023;37(11):e1321–e1322. doi: 10.1111/jdv.19310.
   PubMed Web of Science ®Google Scholar
• Wilkinson NM, Chen HC, Lechner MG, et al. Sex differences in immunity. Annu Rev Immunol. 2022;40(1):75–94. doi: 10.1146/annurev-immunol-101320-125133.
   PubMedGoogle Scholar
• Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol. 2016;16(10):626–638. doi: 10.1038/nri.2016.90.
   PubMed Web of Science ®Google Scholar
• Enos CW, Ramos VL, McLean RR, et al. Comorbid obesity and history of diabetes are independently associated with poorer treatment response to biologics at 6 months: a prospective analysis in Corrona Psoriasis Registry. J Am Acad Dermatol. 2022;86(1):68–76. doi: 10.1016/j.jaad.2021.06.883.
   PubMed Web of Science ®Google Scholar
• Jin JQ, Cronin A, Roberts-Toler C, et al. Sociodemographic and clinical characteristics associated with multiple biologic failure in psoriasis: a 2015-2022 prospective cohort analysis of the CorEvitas Psoriasis Registry. J Am Acad Dermatol. 2023;89(5):974–983. doi: 10.1016/j.jaad.2023.06.058.
   PubMed Web of Science ®Google Scholar
• Song WJ, Yoon HS. Association between complete skin clearance (psoriasis area and severity index 100) and drug survival of biologics in patients with chronic plaque psoriasis: a single-center retrospective study. J Am Acad Dermatol. 2023;89(4):848–851. doi: 10.1016/j.jaad.2023.06.022.
   PubMed Web of Science ®Google Scholar